CeriBell, Inc. (NASDAQ:CBLL – Get Free Report) Director Joseph Taylor sold 10,200 shares of the business’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $27.22, for a total value of $277,644.00. Following the completion of the transaction, the director owned 38,278 shares of the company’s stock, valued at $1,041,927.16. This represents a 21.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Joseph Michael Taylor also recently made the following trade(s):
- On Thursday, August 13th, Joseph Taylor sold 13,095 shares of CeriBell stock. The stock was sold at an average price of $23.40, for a total transaction of $306,423.00.
CeriBell Stock Performance
CBLL traded down $0.12 during mid-day trading on Tuesday, reaching $27.48. 327,271 shares of the company traded hands, compared to its average volume of 373,306. The company’s fifty day moving average price is $25.33 and its 200-day moving average price is $20.95. The stock has a market capitalization of $1.07 billion, a P/E ratio of -14.16 and a beta of 0.86. The company has a quick ratio of 8.79, a current ratio of 8.18 and a debt-to-equity ratio of 0.17. CeriBell, Inc. has a 52-week low of $11.75 and a 52-week high of $28.89.
CeriBell (NASDAQ:CBLL – Get Free Report) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). CeriBell had a negative return on equity of 52.59% and a negative net margin of 67.96%. The business had revenue of $29.34 million during the quarter, compared to the consensus estimate of $29.18 million. On average, sell-side analysts expect that CeriBell, Inc. will post -2.05 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of the company. Strs Ohio purchased a new position in shares of CeriBell in the first quarter valued at $27,000. Legal & General Group Plc bought a new stake in CeriBell in the second quarter worth $53,000. State of Wyoming purchased a new stake in CeriBell during the first quarter valued at $62,000. Quantbot Technologies LP purchased a new stake in CeriBell during the second quarter valued at $112,000. Finally, Y Intercept Hong Kong Ltd bought a new position in CeriBell during the first quarter valued at $341,000.
Analyst Upgrades and Downgrades
A number of equities analysts recently commented on the company. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $29.00 target price on shares of CeriBell in a report on Thursday, September 3rd. TD Cowen boosted their price target on CeriBell from $29.00 to $33.00 and gave the company a “buy” rating in a report on Friday, October 2nd. Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 16th. Barclays raised CeriBell to a “neutral” rating in a research note on Tuesday, August 18th. Finally, BTIG Research reaffirmed a “buy” rating on shares of CeriBell in a research report on Wednesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, CeriBell has an average rating of “Moderate Buy” and a consensus target price of $31.25.
Get Our Latest Stock Analysis on CeriBell
About CeriBell
Ceribell, Inc. develops neurodiagnostic technology for detecting and monitoring seizures. Its products are designed to make electroencephalography (EEG) more accessible in emergency departments and intensive care units, where timely assessment can be important and conventional EEG services may not be readily available. The company’s Ceribell point-of-care EEG system combines a headband with electrodes, a portable recorder and software for viewing and analyzing EEG data. Its Clarity algorithm is designed to help clinicians identify patterns associated with seizure activity, while the system supports remote review by specialists.
Read More
- Five stocks we like better than CeriBell
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
